Registered title, quoted from ClinicalTrials.gov
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07502768, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Pathologically confirmed NK/T-cell lymphoma.
Inclusion criterion 2
Relapsed or refractory disease after at least 1 prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy.
Inclusion criterion 3
Prior treatment with any EZH1/2 or EZH2 inhibitor.
Exclusion criterion 1
Persistent unresolved toxicities greater than CTCAE grade 1 from prior therapy, except alopecia.
Exclusion criterion 10
ECOG performance status 0 to 2.
Inclusion criterion 5
At least 1 measurable or evaluable lesion according to Lugano 2014 criteria.
Inclusion criterion 4
Systemic anti-cancer therapy or investigational therapy within 4 weeks before study treatment.
Exclusion criterion 6
Negative pregnancy test for women of childbearing potential.
Inclusion criterion 9
Pregnancy or breastfeeding.
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07502768, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18 years or older.
- Pathologically confirmed NK/T-cell lymphoma.
- Relapsed or refractory disease after at least 1 prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy.
- At least 1 measurable or evaluable lesion according to Lugano 2014 criteria.
- ECOG performance status 0 to 2.
- Life expectancy greater than 12 weeks.
- Adequate hematologic, hepatic, renal, coagulation, and cardiac function.
- Recovery from prior anti-cancer treatment-related toxicities to CTCAE grade 1 or baseline, except for specified stable irreversible toxicities allowed by the investigator.
- Negative pregnancy test for women of childbearing potential.
- Willingness to use effective contraception.
- Written informed consent.
Exclusion Criteria:
- Prior treatment with any EZH1/2 or EZH2 inhibitor.
- Allogeneic hematopoietic stem cell transplantation within 5 years before study treatment.
- Autologous hematopoietic stem cell transplantation within 3 months before study treatment.
- Requirement for high-dose systemic corticosteroids or other immunosuppressive therapy within 14 days before study treatment, except permitted local/inhaled or short-course use.
- Cytotoxic chemotherapy not discontinued within 14 days before study treatment.
- Systemic anti-cancer therapy or investigational therapy within 4 weeks before study treatment.
- Major surgery within 4 weeks or radiotherapy within 90 days before study treatment.
- Active infection, including active/latent tuberculosis, HIV infection, active hepatitis B or C with detectable viral nucleic acid, or other clinically significant active viral infection.
- Uncontrolled cardiovascular disease.
- Persistent unresolved toxicities greater than CTCAE grade 1 from prior therapy, except alopecia.
- Gastrointestinal disorders or prior intestinal surgery that may impair oral drug absorption.
- Pregnancy or breastfeeding.
- Psychiatric illness or inability to provide informed consent.
- Any other condition that, in the investigator's judgment, makes the patient unsuitable for the study.
Quoted from ClinicalTrials.gov, NCT07502768, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07502768, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.